Alkem Laboratories Launches NeuCeno Cenobamate for Epilepsy in India

Alkem Laboratories Launches NeuCeno in India: New Epilepsy Treatment for Adult Seizures | 📰 LatestLY

Alkem Laboratories has launched NeuCeno (cenobamate) in India for adult partial-onset seizures. The once-daily oral therapy showed up to a 78 per cent seizure reduction in clinical trials. Notably, NeuCeno is a once-daily oral therapy available in strengths ranging from 12.5 mg to 200 mg tablets. Scroll below to know more. 📰 Alkem Laboratories Launches NeuCeno in India: New Epilepsy Treatment for Adult Seizures.

Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India

The once-daily oral therapy is available in five strengths, with clinical studies showing reductions in seizure frequency among adults with uncontrolled focal seizures

Alkem launches NeuCeno for treatment of partial-onset seizures in adult patients

Alkem Laboratories announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy.  NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, […]

Alkem Laboratories launches NeuCeno for treatment of partial-onset seizures in adults

Alkem Laboratories has launched NeuCeno, its branded formulation of cenobamate, for the treatment of partial-onset seizures in adult patients. The company disclosed the product launch through a regulatory filing submitted to the Bombay Stock Exchange.